Glaukos Corporation (GKOS)
USD 87.61
(4.87%)
USD 87.61
(4.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -134.66 Million USD | -35.75% |
| 2022 | -99.19 Million USD | -100.02% |
| 2021 | -49.59 Million USD | 58.79% |
| 2020 | -120.34 Million USD | -880.26% |
| 2019 | 15.42 Million USD | 219.1% |
| 2018 | -12.95 Million USD | -13977.17% |
| 2017 | -92 Thousand USD | -102.03% |
| 2016 | 4.52 Million USD | 112.14% |
| 2015 | -37.24 Million USD | -207.12% |
| 2014 | -12.12 Million USD | 4.06% |
| 2013 | -12.63 Million USD | 34.62% |
| 2012 | -19.33 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -40.83 Million USD | -11.04% |
| 2024 Q2 | -50.54 Million USD | -23.77% |
| 2024 Q3 | -21.4 Million USD | 57.64% |
| 2023 Q3 | -30.44 Million USD | 7.22% |
| 2023 Q2 | -32.81 Million USD | 5.24% |
| 2023 FY | -134.66 Million USD | -35.75% |
| 2023 Q4 | -36.77 Million USD | -20.81% |
| 2023 Q1 | -34.62 Million USD | -10.06% |
| 2022 Q3 | -27.57 Million USD | 39.44% |
| 2022 Q4 | -31.46 Million USD | -14.08% |
| 2022 FY | -99.19 Million USD | -100.02% |
| 2022 Q1 | 5.37 Million USD | 124.58% |
| 2022 Q2 | -45.53 Million USD | -946.87% |
| 2021 Q2 | -17.48 Million USD | -6.15% |
| 2021 Q4 | -21.87 Million USD | -451.08% |
| 2021 Q3 | 6.23 Million USD | 135.64% |
| 2021 FY | -49.59 Million USD | 58.79% |
| 2021 Q1 | -16.46 Million USD | -54.67% |
| 2020 Q1 | -54.05 Million USD | -247.78% |
| 2020 Q2 | -39.89 Million USD | 26.2% |
| 2020 Q3 | -15.74 Million USD | 60.53% |
| 2020 Q4 | -10.64 Million USD | 32.39% |
| 2020 FY | -120.34 Million USD | -880.26% |
| 2019 Q4 | 36.58 Million USD | 370.85% |
| 2019 FY | 15.42 Million USD | 219.1% |
| 2019 Q3 | -13.5 Million USD | -114.08% |
| 2019 Q2 | -6.3 Million USD | -370.12% |
| 2019 Q1 | -1.34 Million USD | -175.44% |
| 2018 Q4 | 1.77 Million USD | 126.87% |
| 2018 FY | -12.95 Million USD | -13977.17% |
| 2018 Q2 | -5.39 Million USD | -99.11% |
| 2018 Q1 | -2.71 Million USD | -369.48% |
| 2018 Q3 | -6.62 Million USD | -22.66% |
| 2017 Q4 | 1 Million USD | -24.08% |
| 2017 FY | -92 Thousand USD | -102.03% |
| 2017 Q1 | 878 Thousand USD | 555.22% |
| 2017 Q2 | -3.3 Million USD | -475.97% |
| 2017 Q3 | 1.32 Million USD | 140.14% |
| 2016 FY | 4.52 Million USD | 112.14% |
| 2016 Q2 | 2.33 Million USD | 159.98% |
| 2016 Q3 | 1.15 Million USD | -50.3% |
| 2016 Q1 | 897 Thousand USD | 139.17% |
| 2016 Q4 | 134 Thousand USD | -88.44% |
| 2015 FY | -37.24 Million USD | -207.12% |
| 2015 Q4 | -2.29 Million USD | -11.33% |
| 2015 Q3 | -2.05 Million USD | 93.56% |
| 2015 Q2 | -31.92 Million USD | -3205.18% |
| 2015 Q1 | -966 Thousand USD | 79.03% |
| 2014 Q2 | -2.07 Million USD | 47.59% |
| 2014 Q3 | -1.48 Million USD | 28.21% |
| 2014 Q1 | -3.95 Million USD | -30.21% |
| 2014 Q4 | -4.6 Million USD | -209.34% |
| 2014 FY | -12.12 Million USD | 4.06% |
| 2013 Q3 | -3.03 Million USD | -7.88% |
| 2013 Q1 | -3.74 Million USD | 0.0% |
| 2013 Q2 | -2.81 Million USD | 24.76% |
| 2013 Q4 | -3.03 Million USD | 0.0% |
| 2013 FY | -12.63 Million USD | 34.62% |
| 2012 FY | -19.33 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott Laboratories | 5.72 Billion USD | 102.353% |
| Allurion Technologies Inc. | -82.3 Million USD | -63.614% |
| Artivion, Inc. | -30.69 Million USD | -338.778% |
| Avanos Medical, Inc. | -61.8 Million USD | -117.898% |
| Butterfly Network, Inc. | -133.69 Million USD | -0.719% |
| Butterfly Network, Inc. | -133.69 Million USD | -0.719% |
| Bio-Rad Laboratories, Inc. | -637.32 Million USD | 78.871% |
| Boston Scientific Corporation | 1.59 Billion USD | 108.453% |
| CONMED Corporation | 64.45 Million USD | 308.91% |
| Edwards Lifesciences Corporation | 1.4 Billion USD | 109.602% |
| Paragon 28, Inc. | -47.84 Million USD | -181.476% |
| Globus Medical, Inc. | 122.87 Million USD | 209.594% |
| Inspire Medical Systems, Inc. | -21.15 Million USD | -536.605% |
| Integer Holdings Corporation | 90.65 Million USD | 248.55% |
| Medtronic plc | 3.67 Billion USD | 103.663% |
| Myomo, Inc. | -8.14 Million USD | -1552.776% |
| Nevro Corp. | -92.21 Million USD | -46.033% |
| Owlet, Inc. | -32.9 Million USD | -309.292% |
| Penumbra, Inc. | 90.95 Million USD | 248.054% |
| Vicarious Surgical Inc. | -71.07 Million USD | -89.474% |
| Smith & Nephew plc | 263 Million USD | 151.202% |
| STERIS plc | 378.23 Million USD | 135.602% |
| Stryker Corporation | 3.16 Billion USD | 104.255% |
| Vapotherm, Inc. | -58.19 Million USD | -131.404% |
| Zimmer Biomet Holdings, Inc. | 1.02 Billion USD | 113.15% |